


19 September 2006

OBJ demonstrates lasting effects

OBJ Limited (OBJ) announced today that new laboratory results had confirmed the ability of the OBJ active through-the-skin drug delivery technology, Dermaportation, to increase and maintain the controlled supply of the hormone ESTRADIOL through the skin for at least 8 hours, even though the technology was active for only 2 hours of that period. The research and development program commenced at OBJ's Perth Laboratories as part of the company's cosmetic and drug delivery research into shorter duration of onset and longer duration of effectiveness. The results have now been independently confirmed by Curtin University's department of Pharmacology.

In the study, Dermaportation was used to set-up a long lasting delivery profile for the hormone Estradiol, using donated human epidermis over an 8 hour period.



The drug delivery technology was applied for only 2 hours of that period and the movement of the drug through the skin was then monitored for a further 6 hours. Drug patches and other drug delivery techniques require "whole of therapy" contact, which can be undesirable in a number of aspects. Poor adhesion, skin irritation and cosmetic unacceptability are significant problems yet to be resolved by traditional drug patches.

"By controlling the movement of drug molecules and the skin's barrier effect as separate processes, OBJ has succeeded in overcoming a number of technical obstacles", said Jeffrey Edwards, head of OBJ's development team. "In cosmetics as well as in drugs delivery, the ability to program the behavior of compounds within the skin for up to 8 to 12 hours into the future open new medical and commercial opportunities".

The company plans to extend this program to include a number of important drugs and skin care molecules in the \$43.2 billion hormone replacement and the \$500 billion cosmetic and skin-care sectors.

OBJ Limited is a transdermal or through-the-skin drug delivery company, specialising in electronic "drug patch" technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently.

END:

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
 Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: jedwards@obj.com.au



OBJ
LIMITED

P
R
E
S
S
R
E
L
E
A
S
E

transdermal drug delivery technology

Background to the Announcement

The OBJ Dermaportation technology has been shown to manage and control the transdermal delivery of a broad range of drugs and therapeutic agents ranging from small difficult molecules such as Caffeine, through to large macro-globular proteins drugs such as vaccines.

OBJ's technology has been independently proven in both in-vitro and in-vivo studies and can manage a broader range of molecular sizes, structures and valencies than other active or passive drug delivery systems. OBJ has been successful in managing the through-the-skin delivery of drugs used in the inflammation, pain, cancer and cosmetic fields.

OBJ's technology is low cost, and can be incorporated into reusable drug patches, (as illustrated) disposable single use drug patches and in a range of packaging systems for OTC and retail use.

Sustainable Benefits

Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localised delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes. These clear commercial benefits may only be achievable if the skin's natural barrier effect can be overcome.

OBJ is the first company to create a broad spectrum through-the-skin delivery system that is kind to the skin, completely reversible, yet can handle drugs range from the small difficult molecules up to the largest and most complex proteins and anti-bodies. OBJ manages an extensive IP portfolio and prosecutes patent applications throughout the world.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University. The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au

